8-K: Lantheus Q2 Revenue Falls, Cuts 2025 Outlook

Lantheus Holdings, Inc. reported a decline in second-quarter revenue and adjusted earnings per share, leading to a significant reduction in its full-year 2025 financial guidance, despite strategic acquisitions and a new share repurchase program.

Summary

• Worldwide revenue for the second quarter of 2025 was $378.0 million, a 4.1% decrease compared to $394.1 million in the prior year period.
• GAAP fully diluted earnings per share increased by 27.3% to $1.12, up from $0.88 in the second quarter of 2024.
• Adjusted fully diluted earnings per share (non-GAAP) decreased by 12.8% to $1.57, down from $1.80 in the same period last year.
• Sales of PYLARIFY, the company's market-leading PSMA PET imaging agent, decreased by 8.3% to $250.6 million.
• Sales of DEFINITY increased by 7.5% to $83.9 million.
• The company announced FDA acceptance of a New Drug Application (NDA) for a new formulation of its piflufolastat F-18 PSMA PET imaging agent, with a PDUFA date set for March 6, 2026.
• The Board of Directors authorized a new share repurchase program of up to $400.0 million of common stock through December 31, 2027, replacing the previous program.
• Lantheus completed the acquisition of Life Molecular Imaging in July 2025, adding Neuraceq, a globally approved beta-amyloid targeted radiodiagnostic for Alzheimer's disease, and an international commercial footprint.
• The company also completed the acquisition of Evergreen Theragnostics in April 2025 for $276.4 million, acquiring OCTEVY and radioligand therapy manufacturing infrastructure.
• Full-year 2025 corporate financial guidance was updated, with revenue now projected between $1.475 billion and $1.51 billion (down from $1.550 billion $1.585 billion) and adjusted fully diluted EPS between $5.50 and $5.70 (down from $6.60 $6.70).

Sentiment

Score: 4

Explanation: While strategic acquisitions and pipeline advancements are positive, the significant decline in Q2 revenue and adjusted EPS, coupled with a substantial downward revision of full-year guidance, indicates operational challenges and increased competitive pressure, leading to a negative short-term financial outlook.

Positives

• GAAP net income increased by 26.9% to $78.8 million for Q2 2025.
• GAAP fully diluted earnings per share increased by 27.3% to $1.12 for Q2 2025.
• Free cash flow increased to $79.1 million in Q2 2025, up from $73.5 million in Q2 2024.
• FDA accepted the NDA for a new formulation of piflufolastat F-18 PSMA PET imaging agent, expected to increase batch size by approximately 50% and enhance supply resilience.
• The acquisition of Life Molecular Imaging immediately expands the commercial portfolio with Neuraceq, a globally approved beta-amyloid targeted radiodiagnostic for Alzheimer's disease.
• FDA approved an updated label for Neuraceq in June 2025, expanding its clinical indication to include diagnostic assessment and identification of appropriate candidates for FDA-approved amyloid-targeting therapies.
• The acquisition of Evergreen Theragnostics adds OCTEVY, a registrational-stage PET imaging agent, and radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.
• The Board authorized a new $400.0 million share repurchase program, reflecting confidence in the long-term strategy and commitment to shareholder value.
• MK-6240, a next-generation tau imaging agent, met its primary endpoints in two pivotal clinical studies, with an NDA submission planned for Q3 2025.

Negatives

• Worldwide revenue decreased by 4.1% to $378.0 million in Q2 2025.
• Sales of PYLARIFY decreased by 8.3% to $250.6 million in Q2 2025, impacted by increased competition in the PSMA PET landscape.
• Adjusted net income (non-GAAP) decreased by 12.8% to $110.6 million in Q2 2025.
• Adjusted fully diluted earnings per share (non-GAAP) decreased by 12.8% to $1.57 in Q2 2025.
• Operating income decreased by 14.4% to $88.0 million in Q2 2025.
• Full-year 2025 revenue guidance was significantly reduced to $1.475 billion $1.51 billion from previous guidance of $1.550 billion $1.585 billion.
• Full-year 2025 adjusted fully diluted EPS guidance was significantly reduced to $5.50 $5.70 from previous guidance of $6.60 $6.70.

Risks

• Continued market expansion and penetration for established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment and the ability to clinically and commercially differentiate products.
• Ability to have third parties manufacture products and the ability to manufacture DEFINITY in the in-house facility, in amounts and at the times needed.
• Availability of raw materials, key components, and equipment, either used in the production of products and product candidates, or in the use by healthcare professionals (HCPs) of products and product candidates, including PET scanners.
• Ability to satisfy obligations under existing clinical development partnerships and license agreements for MK-6240 and NAV-4694, and to further develop and commercialize them as approved products.
• Ability to successfully integrate acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, encompassing unforeseen expenses, accuracy of financial models, unforeseen liabilities, IT system integration, talent retention, and cultural merger.
• Ability to obtain FDA approval for the new F-18 PSMA PET product candidate, complete technology transfer across PET manufacturing facilities, and obtain adequate coding, coverage, and payment.
• Ability to complete the sale of the single-photon emission computerized tomography (SPECT) business to SHINE on proposed terms or anticipated timeline, including regulatory approvals, closing conditions, and realization of expected benefits.
• Ability to obtain FDA approval for LNTH-2501 and PNT2003, and success in the patent litigation associated with PNT2003.
• Cost, efforts, and timing for clinical development, regulatory approval, adequate coding, coverage and payment, and successful commercialization of product candidates and new clinical applications and territories.
• Ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, neurology, and other strategic areas to grow and advance the pipeline.

Future Outlook

The company has significantly revised its full-year 2025 financial guidance downward, now expecting revenue between $1.475 billion and $1.51 billion and adjusted fully diluted EPS between $5.50 and $5.70. This updated outlook reflects the impact of the Life Molecular Imaging acquisition and current business conditions, including increased competition for PYLARIFY. The company plans to submit an NDA for its next-generation tau imaging agent, MK-6240, in the third quarter of 2025 and anticipates an FDA decision on its new piflufolastat F-18 formulation by March 6, 2026. The company also expects to complete the sale of its SPECT business by the end of 2025.

Management Comments

• Brian Markison, CEO, stated: "In the second quarter and the month thereafter, we completed the acquisitions of both Evergreen Theragnostics and Life Molecular Imaging – key steps in executing our strategy to expand capabilities across the radiopharmaceutical value chain, diversify revenue, including with Neuraceq, and drive future growth. At the same time, we navigated increased competition in the PSMA PET landscape, which impacted PYLARIFY performance. We are taking actions to reinforce PYLARIFY’s clinical differentiation and support the value of our PSMA PET franchise. Today, we announced the FDA has accepted our NDA for a new PSMA PET formulation and the Board authorized a new $400 million stock repurchase program, which reflects our confidence in our long-term strategy to deliver value for our business, patients, and shareholders."
• Brian Markison, CEO, also commented on the new PSMA PET formulation: "We are pleased the FDA accepted Aphelion’s NDA for the new piflufolastat F 18 formulation, which we expect will improve patient access due to a significant increase in the number of doses per batch. This formulation is a natural next step in our commitment to advancing PSMA imaging. There is a growing burden of prostate cancer in the U.S. and a clear need for accurate and early detection. Building on PYLARIFY’s proven performance and accuracy, Lantheus is well-positioned for continued leadership in prostate cancer imaging."
• Paul Blanchfield, President, remarked: "We have reached a key milestone and delivered on our commitment to advance prostate cancer imaging through sustainable innovation. By enhancing the efficiency of production, we expect to improve patient access, streamline operations, and support the broader healthcare system’s ability to deliver timely diagnostic imaging."

Industry Context

The radiopharmaceutical industry is experiencing significant growth, particularly in diagnostic and therapeutic applications for oncology and neurology. Lantheus is actively participating in this trend through strategic acquisitions like Life Molecular Imaging (adding Alzheimer's diagnostics) and Evergreen Theragnostics (expanding into neuroendocrine tumors and radioligand therapy manufacturing). The prostate cancer imaging market, where PYLARIFY is a leader, is facing increased competition, which has impacted PYLARIFY's performance. However, the growing burden of prostate cancer, with projected annual cases nearly doubling by 2040, underscores the continued need for advanced diagnostic tools. The company's efforts to enhance PYLARIFY's supply resilience and differentiate its products are critical in this evolving competitive landscape.

Comparison to Industry Standards

• PYLARIFY is cited as the number one ordered PSMA PET imaging agent in the U.S., having been used in over 500,000 scans across 48 states, Puerto Rico, and Washington, D.C., demonstrating its significant market penetration and adoption.
• In a study of patients with recurrent prostate cancer based on rising PSA after therapy, PYLARIFY demonstrated an 86% median true-positive rate based on three independent readers, indicating high diagnostic performance.
• Neuraceq, acquired through Life Molecular Imaging, is a globally approved beta-amyloid targeted radiodiagnostic for Alzheimer's disease, positioning Lantheus in a key area of neurological diagnostics.

Legal Proceedings

• Potential patent litigation associated with PNT2003, an investigational therapeutic candidate.

Stakeholder Impact

• Shareholders may experience negative impacts due to the significant downward revision of full-year financial guidance and decreased PYLARIFY sales, although the new share repurchase program could provide some support.
• Patients are expected to benefit from increased access to PSMA PET imaging through the new piflufolastat F-18 formulation and expanded diagnostic options from acquired assets like Neuraceq and OCTEVY.
• Employees of acquired companies (Life Molecular Imaging, Evergreen Theragnostics) will be integrated into Lantheus, potentially leading to organizational changes.
• Healthcare providers will have access to an enhanced portfolio of radiodiagnostics and potentially increased supply of key imaging agents, supporting timely diagnostic imaging.

Next Steps

• Submit a New Drug Application (NDA) to the FDA for MK-6240, its next-generation tau imaging agent, in the third quarter of 2025.
• Await FDA action on the New Drug Application (NDA) for the new formulation of piflufolastat F-18 PSMA PET imaging agent by the PDUFA date of March 6, 2026.
• Complete the sale of the SPECT business to Illuminated Holdings, Inc. (SHINE Technologies, LLC) by the end of 2025.

Key Dates

Recommendation

The filing presents a mixed bag of strategic advancements and financial setbacks. While the company is actively expanding its portfolio through key acquisitions (Life Molecular Imaging, Evergreen Theragnostics) and advancing its pipeline with promising candidates like the new PSMA PET formulation and MK-6240, the immediate financial performance is concerning. The significant decline in Q2 revenue and adjusted EPS, coupled with a substantial downward revision of full-year 2025 guidance, indicates challenges in the core business, particularly with PYLARIFY facing increased competition. The share repurchase program offers some support, but the reduced outlook suggests a period of adjustment and integration. A 'hold' recommendation is appropriate as the long-term strategic initiatives could eventually bear fruit, but the short-term financial headwinds warrant caution and a wait-and-see approach for investors.

Keywords

Radiopharmaceutical, Prostate Cancer, PET Imaging, PSMA, PYLARIFY, DEFINITY, Alzheimer's Disease, Neuraceq, Theranostics, Oncology, Diagnostics, Share Repurchase, FDA, NDA, Financial Results, Acquisition